Cross-neutralizing antibodies elicited by the Cervarix(®) human papillomavirus vaccine display a range of Alpha-9 inter-type specificities()

The highly efficacious human papillomavirus (HPV) vaccines contain virus-like particles (VLP) representing genotypes HPV16 and HPV18, which together account for approximately 70% of cervical cancer cases. Vaccine-type protection is thought to be mediated by high titer, type-specific neutralizing ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Bissett, Sara L., Draper, Eve, Myers, Richard E., Godi, Anna, Beddows, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969227/
https://www.ncbi.nlm.nih.gov/pubmed/24440205
http://dx.doi.org/10.1016/j.vaccine.2014.01.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969227/
https://www.ncbi.nlm.nih.gov/pubmed/24440205
http://dx.doi.org/10.1016/j.vaccine.2014.01.008

Ejemplares similares